AllQuantitative Report
logoArgusMay 05, 2021

MYGN: Lowering target price to $31.00

Symbols
MYGN
Sector(s)
Healthcare
Rating
Current Price
$31.57
Price Target
$NaN
Earnings Estimate
Summary

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual’s risk of developing a disease.

Subscribe to Yahoo Finance Plus Essential for full access
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Try it Free